1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsAccelerating Medicines Partnership® Heart Failure Program (AMP HF) – ancillary studies/data is sponsored by NHLBI / FNIH (via AMP HF public‑private partnership). Offers researchers access to deep phenotyping and multi‑omics HFpEF datasets (HeartShare registry) for ancillary studies and novel analyses.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Investigators who want to conduct ancillary studies that enhance the HeartShare/AMP-HF study of HFpEF. Must submit proposals for review. Confirm the full requirements in the official notice before applying.
Accelerating Medicines Partnership® Heart Failure Program (AMP HF) – ancillary studies/data is funded by NHLBI / FNIH (via AMP HF public‑private partnership). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
Research Infrastructure Programs - Research Centers is sponsored by Department of Health And Human Services. The Office of Research Infrastructure Programs (ORIP), within the Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI) in the NIH Office of the Director, supports extramural biomedical research by strengthening the infrastructure that enables scientific discovery. ORIP advances human health by fostering the development of critical research models, biomaterials, and technologies; expanding access to state-of-the-art instrumentation and facilities; supporting education and training programs; and assisting small businesses in translating innovative technologies. Through its two divisions, the Division of Comparative Medicine (DCM) and the Division of Construction and Instruments (DCI), ORIP plays a critical role in accelerating biomedical research nationwide. DCM develops and sustains essential research models and biological resources, manages the infrastructure required for their use and distribution, and provides training to ensure investigators have reliable access to high-quality models and facilities. DCI supports shared, cost-effective access to advanced scientific instrumentation, modernizing research facilities, and providing critical equipment that enables transformative biomedical discoveries. Together, DCM and DCI strengthen U.S. competitiveness and ensure the biomedical research community has the infrastructure necessary to address emerging health challenges, prevent disease, promote health, and advance foundational science. This listing is currently active. Program number: 93.3RC. Last updated on 2026-01-28.
Decode the Immunoscience of age-related diseases is sponsored by European Commission — Horizon Europe. Expected Impact: The action under this topic is expected to achieve the following impacts: Accelerate EU access to more cost-effective interventions in an increasingly ageing population by identifying personalised treatment approaches for elderly-onset immune diseases. Decrease disease risk later in life by defining specific prevention strategies based on ageing biomarkers and risk factors. Halt age-associated disease exacerbation by the identification of predictive and digital biomarkers that can stratify patients for early intervention. Improve quality of life for healthy individuals and patients by preventing further health decline, avoiding escalating care costs, and properly stratifying individuals earlier in the diagnostic pathway. Accelerate adoption of innovative diagnostic, preventative, and therapeutic strategies, strengthening the EU’s position as a healthcare innovator. Evaluate digital biomarker as potential regulatory endpoints in the ultimate goal to develop medicines for ‘healthy ageing’. Integrate fragmented research efforts by bringing together health industry sectors and stakeholders to develop clinical and multi-omics data integration capabilities. Enable new data-driven research by building AI infrastructure on existing data and cohorts that no single organisation could develop independently Patients and citizens will benefit from improved medical practice and healthcare solutions, new targeted prevention strategies and ultimately healthier ageing. The action will support EU policy and priorities including the European Health Data Space Regulation (EHDS) and the EU Artificial Intelligence Act, while contributing to European competitiveness in addressing one of society's major challenges. Expected Outcome: The action under this topic must contribute to all of the following outcomes: Researchers will benefit from a better understanding of the potential causal links between chronic inflammatory diseases and biological ageing , and the predictiveness of the accompanying biomarkers could allow for the definition of precise risk profiles for age-associated immune disease onset and exacerbations. Patients will benefit from new early detection strategies as well as new diagnostic approaches to differentiate disease onset in elderly people from onset in younger adults . This will inform a personalised medicine approach to treatment and will in turn help to prevent disease progression. Patients and healthcare professionals will benefit from the repurposing or development of novel therapies for ageing populations with chronic inflammatory diseases and precision medicine approaches that prevent health decline while reducing healthcare costs. Researchers and industry will benefit from the establishment of systematic collaborative approaches for the use of available biobanks across age ranges , immune diseases and comorbidities to adopt innovative approaches (by integration of multi-omics, immunophenotyping, digital biomarkers, ageing clocks, and artificial intelligence (AI) with comprehensive patient information). Patients and healthcare professionals will benefit from deeper insights into treatment response and the evaluation of the impact of ageing on treatment effectiveness. Industry and researchers will benefit from the establishment of regulatory pathways for novel intervention strategies and biomarkers , leading to the faster clinical development of drugs that improve age-associated disease exacerbations, ultimately enabling the translation of research findings into therapeutic solutions for vulnerable patient populations. This includes the field of digital biomarkers and their use in monitoring activity, strength and fatigue as exemplary readouts. Scope: The global population is undergoing an unprecedented demographic shift, with the number of individuals aged 65 and older projected to double by 2050, presenting one of the most significant public health challenges of our time. The transition to an ageing society Programme areas: Global Challenges and European Industrial Competitiveness, Health, Innovative Health Initiative, Horizon Europe (HORIZON) Keywords: Artificial intelligence, Biomarkers, Chronic diseases, Immunology, Innate immunity and inflammation, Molecular biology, Decode the Immunoscience of age-related diseases, IHI, IHI JU, Innovative Health Initiative, Innovative Health Initiative Joint Undertaking, Joint Undertaking Deadline stages: 2026-10-08, 2027-04-21
NSF 26-501 (CAMEL) commits $9 million to build AI-ready K-12 mathematics datasets across 6–7 awards of up to $1.5 million each. The money is co-supported by the Walton Family Foundation — and the solicitation bars WFF staff and partners from participating in any capacity, prohibits voluntary cost sharing, and requires reports be shared with the foundation after NSF review. Here's how the public-private structure works, and what Phase II means for teams already in.
Read articleA new Partnership for Public Service report documents 118,000 science-related federal departures between September 2024 and February 2026 — Forest Service and NSF down a third, SAMHSA down 42 percent. Project grant obligations from science agencies dropped 24 percent from 2024 to 2025. On June 3, Johns Hopkins announced a $60M annual Research Resilience Fund. Here is what the data and the institutional response mean for grant applicants.
Read articleOpenAI's $122 billion round dwarfs the $3.3 billion the U.S. spends on non-defense AI R&D. The National Security Commission recommended $32 billion by now. We're at one-tenth of that target. What the private-public AI funding gulf means for researchers.
Read article